TRENDING :  Market Movers  |  Top 50   AAPL (-0.23%)    FB (-0.89%)    KO (-0.77%)    AMZN (-0.91%)    UGAZ (4.96%)    VXXB (-3.5%)    MGM (3.07%)    MDB (1.02%)    KRE (2.17%)    AMD (2.38%)    ABMD (1.19%)    AA (0.25%)    IVC (12.08%)    HTGM (2.18%)    GOOS (-2.76%)    GH (4.51%)    GEVO (1.66%)    FUV (-31.27%)    FCEL (12.84%)    DIS (1.75%)    DGAZ (-4.98%)    CRON (2.26%)    CRM (-0.27%)    CGC (3.13%)    CAT (2.7%)

 BSX - Boston Scientific Corporation

$40.01 [0.09][0.23%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $45.00
Low $42.00
Average $43.50
Current $40.01

CompanyAnalyst NamePT ActionActionRatingTargetDate
Credit SuisseAnnouncesInitiates Coverage OnStrong Buy$42.0012/18/18
UBSAnnouncesInitiates Coverage OnBuy$45.0011/28/18
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.


Service NameTrader% Success
LavaPitSteve Pitkin55.00 %Follow
Options MannThomas Mann40.00 %Follow


Health Care Sector Update for 02/15/2019: BSX,LLY,LOXO,ORPN,AKAO

Top Health Care StocksTop Health Care Stocks JNJ 1 01 JNJ 1 01 PFE 1 12 PFE 1 12 ABT 1 47 ABT 1 47 MRK 0 99 MRK 0 99 AMGN 0 43 AMGN 0 43 Health care stocks continued to rise this afternoon including a nearly 1 3 gain for the NYSE Health Care Index in late trade Shares of

BSX is Breaking Out for the First Time Since September 2018

InvestorPlace Stock Market News Stock Advice amp Trading Tips To receive further updates on this 160 Boston Scientific NYSE BSX trade as well as an alert when it s time to take profits 160 sign up for a risk free trial of

Boston Scientific Benefits From New Buyouts & Product Launch

On Feb 12 we issued an updated research report on Boston Scientific Corporation BSX The company s recent acquisitions have added various products though many are under development with immense potential to its portfolio The stock carries a Zacks Rank 3 Hold Over the past three

Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp

Tuesday February 12 2019 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Disney DIS Eli Lilly LLY and U S Bancorp USB These research reports have been hand picked from

3 Big Stock Charts for Thursday: FirstEnergy, Boston Scientific and Mondelez

InvestorPlace Stock Market News Stock Advice amp Trading Tips Stocks finally found their ceiling right where it would have been expected The S amp P 500 s close of 2731 61 was down 0 22 from Tuesday s last trade with the 200 day moving average line confirming its role

Company News For Feb 7, 2019

Capri Holdings Ltd s CPRI shares surged 11 3 after reporting third quarter fiscal 2019 adjusted earnings per share of 1 76 surpassing the Zacks Consensus Estimate of 1 57 Shares of Boston Scientific Corp BSX climbed 2 7 after posting fourth quarter 2018 adjusted

Boston Scientific (BSX) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Boston Scientific NYSE BSX Q4 2018 Earnings Conference Call Feb 6 2019 8 00 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator Ladies

Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip

Boston Scientific Corporation BSX posted adjusted earnings per share EPS of 39 cents in the fourth quarter of 2018 up 14 7 from the year ago quarter Earnings surpassed the Zacks Consensus Estimate of 37 cents Further adjusted EPS exceeded the company s guided range of 30 32

Wednesday Sector Leaders: Healthcare, Technology & Communications

In afternoon trading on Wednesday Healthcare stocks are the best performing sector up 0 1 Within that group Boston Scientific Corp Symbol BSX and Gilead Sciences Inc Symbol GILD are two large stocks leading the way showing a gain of 2 6 and 2 4 respectively Among healthcare

Boston Scientific (BSX) Q4 Earnings and Revenues Beat Estimates

Boston Scientific BSX came out with quarterly earnings of 0 39 per share beating the Zacks Consensus Estimate of 0 37 per share This compares to earnings of 0 34 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings

Boston Scientific Q4 18 Earnings Conference Call At 8:00 AM ET

Boston Scientific Q4 18 Earnings Conference Call At 8:00 AM ET

Pre-Market Earnings Report for February 6, 2019 : LLY, GM, BSX, REGN, HUM, CTSH, CMI, GSK, FDC, TTWO, BIP, JEC

The following companies are expected to repor t earnings prior to market open on 02 06 2019 Visit our Earnings Calendar for a full list of expected earnings releases Eli Lilly and Company LLY is reporting for the quarter ending December 31 2018 The

Stocks Extend Recent Upward Trend On Positive Momentum - U.S. Commentary

Stocks Extend Recent Upward Trend On Positive Momentum - U.S. Commentary

Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?

Boston Scientific Corporation 160 BSX is scheduled to report fourth quarter 2018 results before the opening bell on Feb 6 In the las t report ed quarter the company s earnings per share beat the Zacks Consensus Estimate by 2 94 Moreover it delivered positive earnings surprises in

Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Wall Street expects a year over year increase in earnings on higher revenues when Boston Scientific BSX reports results for the quarter ended December 2018 While this widely known consensus outlook is important in gauging the company s earnings picture a powerful factor that could impact

VREX vs. BSX: Which Stock Is the Better Value Option?

Investors with an interest in Medical Products stocks have likely encountered both VAREX IMAGING VREX and Boston Scientific BSX But which of these two companies is the best option for those looking for undervalued stocks Let s take a closer look The best way to find great value stocks

Boston Scientific Says VICI Stent Meets Primary Effectiveness Endpoint

Boston Scientific Says VICI Stent Meets Primary Effectiveness Endpoint